Scientists identify new target for melanoma immunotherapy


QIMR Berghofer research has found a new reason why some melanoma patients do not respond well to immunotherapy – a discovery that could lead to better-tailored treatments for the potentially deadly cancer.

Australia has the highest rate of melanoma in the world. The Australian Institute of Health and Welfare estimates there were more than 15,000 cases of melanoma in Australia last year, and more than 1700 deaths.

The research, led by QIMR Berghofer Senior Scientist and Immunology Department Coordinator Professor Mark Smyth, found high levels of the protein CD155 in human melanoma cells made the skin cancer harder to treat with immunotherapy.

“Our study has highlighted the central importance of CD155 to the effectiveness of immunotherapy for patients with metastatic melanoma – something that hasn’t been shown before in humans,” Professor Smyth said.

“The tumour appears to be using the CD155 molecule to escape being hunted down by immune cells, called T-cells, and to also resist being killed off by immunotherapy.”

The CD155 protein is expressed by nearly all cancer cells and less so by normal cells, including some immune cells. It is part of a family of adhesive proteins that are important in cell to cell interaction.

“Modern immunotherapy treatments have been quite successful in helping unleash our immune systems to kill melanoma tumour cells, but in some people the tumour cells remain disguised and treatments don’t work, often leading to death,” Professor Smyth said.

“We found high levels of CD155 in melanoma cells seem to help tumours evade detection by the T-cells and trick them into leaving the tumour alone. The tumour CD155 appears to wound the T-cells during the interaction, reducing their capacity to subsequently recognise and kill tumour cells.

“Reducing tumour CD155 in people with metastatic melanoma may be a way to improve the effectiveness of immunotherapy for them and save the lives of many more people.”

The researchers used new imaging technology to examine pre-treatment tumour samples collected from patients in Brisbane, Sydney and Italy and correlated the levels of CD155 with the patients’ survival outcomes.

Contributing author and Royal Brisbane and Women’s Hospital Medical Oncologist, Dr Elizabeth Ahern, said the imaging showed very high levels of CD155 in melanoma cells.

“We found patients with higher levels of the protein had worse health outcomes and didn’t respond well to immunotherapies,” Dr Ahern said.

“It’s the quantity of CD155 proteins that makes it so immune evasive. It appears the T-cells can’t kill the tumour because the CD155 proteins are unbalancing the T-cells and turning them off before they can do their job.

“Currently there are no therapeutics used for melanoma that target CD155, so we hope to explore that pathway.  We now want to focus on designing new immunotherapies that target the CD155 proteins to get them off the tumour.”

The study findings have been published in the journal Clinical Cancer Research.

The study builds on Professor Smyth’s 2018 research that showed CD155 in both tumour and immune cells was important for tumour growth and spread.

Professor Smyth and his team hope to expand the study to examine if CD155 plays a role in how other cancers respond to immunotherapies.

Community Health & Wellness Science & Research

QIMR Berghofer Medical Research Institute :
PO Royal Brisbane Hospital, Brisbane, QLD, 4029, Brisbane
07 3845 3752
QIMR Berghofer Medical Research Institute
Showing 10+ recent articles for this business
Pessimistic outlook on life linked to life expectancy 29 July 2020 | A new QIMR Berghofer Medical Research Institute study has found people who are strongly pessimistic about the future are at greater risk of dying earlier than those who are not pessimists. More information...
New keys found for unlocking head and neck cancer treatment 28 July 2020 | QIMR Berghofer scientists say the discovery of new cellular immunotherapy targets for a deadly type of head and neck cancer, caused by human papillomavirus (HPV), could lead to better survival rates. More information...
Scientists identify new target for melanoma immunotherapy 30 June 2020 | QIMR Berghofer research has found a new reason why some melanoma patients do not respond well to immunotherapy – a discovery that could lead to better-tailored treatments for the potentially deadly cancer. More information...
Heart research to be revolutionised thanks to $8 million funding boost 25 June 2020 | Queensland researchers will begin developing a comprehensive ‘encyclopedia’ of the heart in a world-first project that, if successful, will revolutionise cardiac research and treatment. More information...
Researchers stimulate improvements in Parkinson's treatment 23 June 2020 | New research led by QIMR Berghofer Medical Research Institute has identified ways to make the most widely-used advanced treatment for Parkinson’s disease – deep brain stimulation therapy – more effective and... More information...
Blood cancer find raises new treatment hopes 16 June 2020 | New QIMR Berghofer research has identified how an early genetic change in blood and bone marrow cells paves the way for the development of some blood cancers. More information...
New evidence of dangers of high-fat diet on pre-cancerous condition 08 June 2020 | New QIMR Berghofer research indicates that a high-fat diet over a long period of time may induce early Barrett’s oesophagus, a precursor condition to oesophageal cancer. More information...
Study finds new clues in eye cancer 19 May 2020 | About five per cent of melanomas in the eye are caused by exposure to sunlight, while the majority are not, a new study by QIMR Berghofer and Queensland Ocular Oncology Service has found. More information...
Queenslanders needed to help find potential COVID-19 immunotherapy treatment 14 May 2020 | QIMR Berghofer scientists are urging Queenslanders who have recovered from COVID-19 to help them discover how the human immune system fights the disease – and hopefully develop immunotherapies to treat very sick... More information...
Scientists to trial rheumatoid arthritis drug in ICU patients with COVID-19 09 May 2020 | Queensland researchers are preparing to begin a clinical trial of a drug that regulates inflammation in the hope it may help save the lives of critically ill patients with COVID-19. More information...

comments powered by Disqus

All articles submitted by third parties or written by My Sunshine Coast come under our Disclaimer / Terms of Service